We are live on ! Find out more
HQL

abrdn Life Sciences Investors

70 hedge funds and large institutions have $81.3M invested in abrdn Life Sciences Investors in 2020 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 25 increasing their positions, 21 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more capital invested

Capital invested by funds: $65.2M → $81.3M (+$16.1M)

19% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 21

1% more funds holding

Funds holding: 6970 (+1)

9% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 11

0.16% more ownership

Funds ownership: 19.12%19.28% (+0.16%)

Holders
70
Holders Change
+1
Holders Change %
+1.45%
% of All Funds
1.44%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
12
Increased
25
Reduced
21
Closed
11
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
WT
76
Washington Trust
Rhode Island
-$4K -289 Closed
Fidelity Investments
77
Fidelity Investments
Massachusetts
-$17 -1 -50%
JP Morgan Chase
78
JP Morgan Chase
New York
+$34 +2 New
AWM
79
Avior Wealth Management
Nebraska
+$51 +3 New

HQL Hedge Fund Activity: Q2 2020 in Review

70 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in abrdn Life Sciences Investors (HQL) for Q2 2020, worth a combined $81.3M — up 25% from $65.2M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new HQL positions and 11 closed out — a net gain of 1 holder — while 25 added to existing stakes and 21 trimmed.

The largest buyer was 1832 Asset Management, adding an estimated $2.56M. The largest seller was Wolverine Asset Management, cutting an estimated $5.19M.

  • 70 institutional investors held abrdn Life Sciences Investors (HQL) as of Q2 2020, up from 69 in Q1 2020.
  • Funds reported $81.3M of abrdn Life Sciences Investors stock for Q2 2020, up 25% quarter-over-quarter.
  • 12 funds opened new abrdn Life Sciences Investors positions in Q2 2020 and 11 closed out, a net change of +1 holder.
  • The largest abrdn Life Sciences Investors buyer in Q2 2020 was 1832 Asset Management, an estimated $2.56M added.
  • The largest abrdn Life Sciences Investors seller in Q2 2020 was Wolverine Asset Management, an estimated $5.19M sold.

Based on aggregated 13F filings for Q2 2020.